Anne Wojcicki, 23andMe

23andMe CEO Anne Wojcicki speaks on stage during 'The Fast Company Innovation Festival' - Data + Drugs: The New Evolution Of Drug Making With 23andMe And Sprout on November 10, 2015 in New York City.
  • Company valuation: $1 billion

23andMe, which is named after the 23 pairs of chromosomes in a human cell, has two women co-founders: Anne Wojcicki and Linda Avey.

The company is best known for collecting the spit of customers in exchange for information about their genetic history, health, and physical traits based on their DNA. It also leverages user data for disease research and developing drug therapies.

23andMe secured $250 million in funding in September from venture firm Sequoia Capital.

Wojcicki is the firm's CEO.

First published November 3, 2017: 10:08 AM ET

Partner Offers

Most Popular